Tolerogenic Dendritic Cells Generated with Different Immunosuppressive Cytokines Induce Antigen-specific Anergy and Regulatory Properties in Memory CD4+ T Cells
Overview
Authors
Affiliations
Dendritic cells (DCs) are professional APCs involved in the initiation of both immunity and immunological tolerance. In autoimmune diseases or graft rejections, most reactive lymphocytes are effector/memory cells. It is believed that memory T cells are more resistant to tolerance induction than naive lymphocytes; however, studies on mechanisms for their efficient tolerization are still scarce. In this study, we generated human monocyte-derived DCs by culture with GM-CSF and IL-4 (control DCs), as well as tolerogenic DCs (tDCs) by adding IL-10, IL-10/TGF-beta1, or IL-10/IL-6. Cells were maturated with TNF-alpha/PGE(2). Compared with control DCs, tDCs had similar expression of HLA-DR, CD80, and CD86, lower expression of CD40, higher levels of macrophage markers, enhanced endocytic ability, increased secretion of IL-6, IL-10 (only tDCs generated with IL-10 and tDCs generated with IL-10/IL-6), and PGE(2), and lower secretion of IL-12 and IL-23. In vitro, tDCs had the capacity to induce anergy in tetanus toxoid-specific memory CD4(+) T cells, whereas the proliferative response to an unrelated Ag was intact. Anergy could be reverted upon exposure to IL-2. tDC-primed T cells have low suppressive ability. Nevertheless, the generation of both anergic and regulatory T cells was more efficient with tDCs generated with IL-10/TGF-beta1. Microarray-based gene expression profiling reflected modulated expression of several transcripts in tDCs. Surface CLIP-HLA-DR complexes and intracellular thrombospondin-1 were increased in the three tDCs. CD39 was highly expressed only in tDC-TGF, which correlated with increased adenosine production. We propose that these molecules, together with IL-10 and prostanoids, are key factors to induce Ag-specific tolerance in memory T cells.
Mechanistic insight of curcumin: a potential pharmacological candidate for epilepsy.
Khatoon S, Kalam N Front Pharmacol. 2025; 15():1531288.
PMID: 39845785 PMC: 11752882. DOI: 10.3389/fphar.2024.1531288.
Scroggins S, Schlueter A Cells. 2023; 12(19).
PMID: 37830587 PMC: 10571850. DOI: 10.3390/cells12192372.
Czaja A Dig Dis Sci. 2023; 68(11):4098-4116.
PMID: 37755606 PMC: 10570239. DOI: 10.1007/s10620-023-08118-6.
Gray G, Scroggins D, Wilson K, Scroggins S Int J Mol Sci. 2023; 24(17).
PMID: 37686399 PMC: 10487605. DOI: 10.3390/ijms241713594.
Inflammatory and tolerogenic myeloid cells determine outcome following human allergen challenge.
Voskamp A, Tak T, Gerdes M, Menafra R, Duijster E, Jochems S J Exp Med. 2023; 220(9).
PMID: 37428185 PMC: 10333709. DOI: 10.1084/jem.20221111.